Comparing GeoVax Labs (NASDAQ:GOVX) and Mirum Pharmaceuticals (NASDAQ:MIRM)

GeoVax Labs (NASDAQ:GOVX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for GeoVax Labs and Mirum Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
Mirum Pharmaceuticals	1	0	13	1	2.93

GeoVax Labs presently has a consensus target price of $3,600.00, suggesting a potential upside of 166,566.67%. Mirum Pharmaceuticals has a consensus target price of $155.56, suggesting a potential upside of 64.43%. Given GeoVax Labs’ higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Mirum Pharmaceuticals.

Insider and Institutional Ownership

6.1% of GeoVax Labs shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares GeoVax Labs and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Mirum Pharmaceuticals	-134.75%	-97.25%	-12.59%

Volatility and Risk

GeoVax Labs has a beta of 3.85, meaning that its stock price is 285% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Earnings & Valuation

This table compares GeoVax Labs and Mirum Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49 million	6.39	-$21.47 million	($11.34)	-0.19
Mirum Pharmaceuticals	$670.78 million	9.21	-$23.36 million	($15.47)	-6.12

GeoVax Labs has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Mirum Pharmaceuticals beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.